Dataset Information


Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers.

ABSTRACT: Aberrant gene expression is a hallmark of cancer. Although transcription is traditionally considered 'undruggable', the development of CRISPR-associated protein 9 (Cas9) systems offers enormous potential to rectify cancer-associated transcriptional abnormalities in malignant cells. However delivery of this technology presents a critical challenge to overcome in order to realize clinical translation for cancer therapy. In this article we demonstrate for the first time, a fully synthetic strategy to enable CRISPR-mediated activation (CRISPRa) of tumour suppressor genes in vivo using a targeted intravenous approach. We show this via highly efficient transcriptional activation of two model tumour suppressor genes, Mammary Serine Protease Inhibitor (MASPIN, SERPINB5) and cysteine-rich 61/connective tissue growth factor/nephroblastoma-overexpressed 6 (CCN6, WISP3), in a mouse model of breast cancer. In particular, we demonstrate that targeted intravenous delivery of can be achieved using a novel nanoscale dendritic macromolecular delivery agent, with negligible toxicity and long lasting therapeutic effects, outlining a targeted effective formulation with potential to treat aggressive malignancies.

SUBMITTER: Kretzmann JA 

PROVIDER: S-EPMC6761875 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6526230 | BioStudies
2020-01-01 | S-EPMC7261405 | BioStudies
2019-01-01 | S-EPMC6858551 | BioStudies
2019-01-01 | S-EPMC6710252 | BioStudies
2020-01-01 | S-EPMC7089667 | BioStudies
1000-01-01 | S-EPMC6056518 | BioStudies
2018-01-01 | S-EPMC5774230 | BioStudies
2019-01-01 | S-EPMC6816553 | BioStudies
2020-01-01 | S-EPMC6971260 | BioStudies
2017-01-01 | S-EPMC5641601 | BioStudies